Abstract
Chronic urticaria is an itchy skin disease, which is treated with antihistamines; however, a large group of patients are unresponsive to antihistamines alone and are thus treated with omalizumab, although a small fraction of these patients have particularly recalcitrant disease. Currently, there are no reliable biomarkers available to assess disease activity/severity and treatment response in chronic urticaria patients. However, it has been reported that high levels of d-dimer are observed during disease activity and are significantly reduced during periods of remission. We present a focused overview of studies investigating plasma d-dimer level as a biomarker for disease activity and treatment response in patients with chronic urticaria.
Originalsprog | Engelsk |
---|---|
Tidsskrift | European Journal of Dermatology |
Vol/bind | 28 |
Udgave nummer | 6 |
Sider (fra-til) | 731-735 |
ISSN | 1167-1122 |
DOI | |
Status | Udgivet - 2018 |